CN109963846A - 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 - Google Patents
一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 Download PDFInfo
- Publication number
- CN109963846A CN109963846A CN201880004384.0A CN201880004384A CN109963846A CN 109963846 A CN109963846 A CN 109963846A CN 201880004384 A CN201880004384 A CN 201880004384A CN 109963846 A CN109963846 A CN 109963846A
- Authority
- CN
- China
- Prior art keywords
- solvent
- crystal form
- crystallization
- angle
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
本发明涉及一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法。具体而言，本发明涉及一种表皮生长因子受体(EGFR)抑制剂的二马来酸盐的Ⅳ晶型及其制备方法。该Ⅳ晶型具备良好的化学稳定性和晶型稳定性，可更好地用于临床治疗。
Description
PCT国内申请，说明书已公开。
Claims (7)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710667478 | 2017-08-07 | ||
| CN201710667478.3 | 2017-08-07 | ||
| PCT/CN2018/098950 WO2019029477A1 (zh) | 2017-08-07 | 2018-08-06 | 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109963846A true CN109963846A (zh) | 2019-07-02 |
Family
ID=65273340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880004384.0A Pending CN109963846A (zh) | 2017-08-07 | 2018-08-06 | 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN109963846A (zh) |
| WO (1) | WO2019029477A1 (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102020639A (zh) * | 2009-09-14 | 2011-04-20 | 上海恒瑞医药有限公司 | 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用 |
| CN103539783A (zh) * | 2012-07-12 | 2014-01-29 | 江苏恒瑞医药股份有限公司 | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 |
-
2018
- 2018-08-06 CN CN201880004384.0A patent/CN109963846A/zh active Pending
- 2018-08-06 WO PCT/CN2018/098950 patent/WO2019029477A1/zh active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102020639A (zh) * | 2009-09-14 | 2011-04-20 | 上海恒瑞医药有限公司 | 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用 |
| CN103539783A (zh) * | 2012-07-12 | 2014-01-29 | 江苏恒瑞医药股份有限公司 | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019029477A1 (zh) | 2019-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2631321C2 (ru) | Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения | |
| RU2672563C1 (ru) | Кристаллы 3,5-дизамещенного бензолалкинильного соединения | |
| EA015677B1 (ru) | СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА | |
| CN110049980A (zh) | 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法 | |
| CN104109124B (zh) | 卡博替尼·0.5苹果酸盐的晶体 | |
| Fang et al. | A series of stable, metastable and unstable salts of Imatinib with improved solubility | |
| CN108779122A (zh) | 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法 | |
| CN108778282A (zh) | 一种GnRH受体拮抗剂的结晶形式及其制备方法 | |
| CN109937200A (zh) | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 | |
| CN108884099A (zh) | 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法 | |
| CN108778280A (zh) | 一种GnRH受体拮抗剂的多晶型及其制备方法 | |
| Maniukiewicz et al. | Structural characterization and Hirshfeld surface analysis of racemic baclofen | |
| US20220017533A1 (en) | Crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them | |
| EA036295B1 (ru) | Твердые формы замещенных 5,6-дигидро-6-фенилбензо[f]изохинолин-2-аминовых соединений | |
| CN109963846A (zh) | 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 | |
| CN109206410A (zh) | 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 | |
| WO2022063229A1 (zh) | 含芳氨基喹唑啉的化合物的盐及其制备方法和应用 | |
| WO2018149309A1 (zh) | 4-苯基噻唑衍生物的晶型及其制备方法 | |
| US10150739B2 (en) | Crystalline form of androgen receptor inhibitor and preparation method thereof | |
| TWI770934B (zh) | 酪胺酸激酶抑制劑的一馬來酸鹽的晶型及其製備方法 | |
| CN109206407A (zh) | 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 | |
| TWI666207B (zh) | 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法 | |
| US8946474B2 (en) | Polymorphic form of a calcimimetic compound | |
| TW202124373A (zh) | 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法 | |
| JP7034430B2 (ja) | 重水素化インドールアミン２，３－ジオキシゲナーゼ阻害剤及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190702 |
|
| WD01 | Invention patent application deemed withdrawn after publication |